223 completed. 223 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 223 | Completed 223 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 mRNA-1273 (Moderna COVID-19 vaccine) - COVID-19 | Phase 4 | Completed | Tor Biering-Sørensen | 41060 | 2025-12-11 | 2026-10-06 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations mRNA-1283.251 Variant-containing Formulation - COVID-19 | Phase 4 | Completed | ModernaTX, Inc. | 832 | 2025-07-21 | 2026-07-07 |
| Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes High-Dose Influenza Vaccine, Standard-Dose Influenza Vaccine - Influenza | Phase 4 | Completed | Tor Biering-Sørensen | 466320 | 2025-05-31 | 2025-09-12 |
| Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP) Faropenem, Co-amoxiclav, Clarithromycin 500 mg - Pneumonia, Community-Acquired, Bacterial Pneumonia | Phase 4 | Completed | Dr. Md. Alimur Reza | 129 | 2025-02-20 | 2026-08-04 |
| An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. Remdesivir - SARS-CoV-2 Infection, COVID-19 | Phase 4 | Completed | University of Derby | 73 | 2024-10-08 | 2026-02-20 |
| Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine - COVID-19, Vaccine-Preventable Diseases | Phase 4 | Completed | Novavax | 660 | 2024-09-19 | 2026-06-02 |
| Aspiration Pneumonia in Cerebrovascular Stroke Patients Suffering From Bulbar Palsy Enteral nutrtion, TPN - Aspiration Pneumonia | Phase 4 | Completed | Ain Shams University | 50 | 2024-05-05 | 2026-08-04 |
| Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia Amikacin (Inhalation), Standard-of-Care Intravenous Antibiotics - Ventilator Associated Pneumonia ( VAP) | Phase 4 | Completed | Postgraduate Medical Institute, Lahore | 90 | 2024-01-05 | 2026-01-27 |
| The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing) - COVID-19, Vaccine-Preventable Diseases | Phase 4 | Completed | Sarang K. Yoon, DO, MOH | 1188 | 2023-11-22 | 2026-01-28 |
| The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D) Phenoxymethylpenicillin 1.2 MIE 4 times daily - Community-acquired Pneumonia | Phase 4 | Completed | Research Unit for General Practice in Aalborg | 307 | 2023-11-13 | 2026-10-22 |
| Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine) - Influenza, COVID-19 | Phase 4 | Completed | Duke University | 455 | 2023-09-25 | 2025-06-13 |
| Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial abatacept infusion, Placebo group - COVID-19 | Phase 4 | Completed | University of Minnesota | 285 | 2023-07-06 | 2026-08-31 |
| Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity SYS6006 - COVID-19, SARS-CoV-2 Infection | Phase 4 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 2052 | 2023-05-23 | 2026-09-22 |
| The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients Chlorhexidine digluconate, povidone iodine - COVID-19 | Phase 4 | Completed | King Abdulaziz University | 60 | 2023-05-18 | 2025-06-12 |
| Post-COVID-19 Chronic Fatigue Syndrome Synthetic Vitamin B1 - Post-COVID-19 Syndrome, Post-COVID Syndrome | Phase 4 | Completed | ClinAmygate | 528 | 2023-01-08 | 2025-03-10 |
| Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients Ambroxol Hydrochloride, Standard Therapy - Severe Pneumonia, Community-acquired Pneumonia | Phase 4 | Completed | National University of Malaysia | 32 | 2023-01-07 | 2023-12-27 |
| A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine - Influenza | Phase 4 | Completed | Tor Biering-Sørensen | 332438 | 2022-09-22 | 2025-09-12 |
| Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients Casirivimab and Imdevimab Drug Combination, Remdesivir, Favipiravir - COVID-19 | Phase 4 | Completed | Mansoura University Hospital | 265 | 2022-09-02 | 2023-07-25 |
| Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial Sinovac, AZD1222, BNT162b2 - COVID-19 | Phase 4 | Completed | Albert B. Sabin Vaccine Institute | 2354 | 2022-07-05 | 2024-01-30 |
| Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19 Sotrovimab - COVID-19 | Phase 4 | Completed | GlaxoSmithKline | 217 | 2022-07-01 | 2026-10-06 |
Showing 20 of 223. Sign in to see all of them.
COVID-19 (113) · Pneumonia, Ventilator-Associated (24) · Community-Acquired Pneumonia (16) · Coronavirus Infections (16) · Influenza, Human (11) · Infections (10) · Pneumonia, Pneumococcal (8) · Healthcare-Associated Pneumonia (7) · Pneumonia, Bacterial (6) · Pulmonary Disease, Chronic Obstructive (6) · Respiratory Tract Infections (6) · Diarrhea (5) · Pneumonia, Viral (5) · Acquired Immunodeficiency Syndrome (4)
Respiratory Tract Diseases (221) · Respiratory Tract Infections (217) · Infections (213) · Lung Diseases (212) · RNA Virus Infections (122) · Virus Diseases (121) · Coronaviridae Infections (113) · Nidovirales Infections (113) · Pneumonia, Viral (111) · Coronavirus Infections (98) · Pathological Conditions, Signs and Symptoms (58) · Pathologic Processes (45) · Disease Attributes (38) · Iatrogenic Disease (27)
sinovac COVID-19 vaccine (13) · Amoxicillin (9) · BNT162 Vaccine (9) · 2019-nCoV Vaccine mRNA-1273 (8) · Amoxicillin-Potassium Clavulanate Combination (7) · Ceftriaxone (7) · Sodium Chloride (7) · Standard of Care (7) · Pneumococcal Vaccines (6) · Azithromycin (5) · Enoxaparin (5) · Heptavalent Pneumococcal Conjugate Vaccine (5) · Vancomycin (5) · 23-valent pneumococcal capsular polysaccharide vaccine (4) · Dexamethasone (4)
Pfizer (8) · Jiangsu Province Centers for Disease Control and Prevention (6) · Sinovac Research and Development Co., Ltd. (6) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Ain Shams University (3) · Sinovac Biotech Co., Ltd (3) · Sinovac Life Sciences Co., Ltd. (3) · Sutep Jaruratanasirikul (3) · Tor Biering-Sørensen (3) · Assistance Publique Hopitaux De Marseille (2) · Centre Hospitalier Universitaire de Besancon (2) · China National Biotec Group Company Limited (2) · Duke University (2) · FMH College of Medicine and Dentistry (2) · Forest Laboratories (2)
United States (55) · China (30) · Spain (17) · Brazil (11) · Denmark (10) · France (10) · Egypt (8) · India (8) · Belgium (7) · Netherlands (7) · Thailand (7) · Canada (6) · Germany (6) · United Kingdom (6) · Greece (5)
Jing-Xin Li, PhD (3) · Sutep Jaruratanasirikul, MD (3) · Aijaz Zeeshan Khan Chachar, MBBS,FCPS (2) · Amy Ginsburg, MD, MPH (2) · Avni Thakore, MD (2) · Dongjuan Zhang (2) · Fubing Wang (2) · Jens Lundgren, Professor (2) · Qing Wang (2) · Qiuyun Deng (2) · Ruizhi Zhang (2) · Shicheng Guo (2)
PMID 33502773, PMID 35244208, PMID 35012490, PMID 36658045, PMID 37489818, PMID 10404452, PMID 11225528, PMID 11505791, PMID 14998500, PMID 15867027, PMID 16490989, PMID 17090560, PMID 17099299, PMID 17872488, PMID 18545744, PMID 18707849, PMID 18719064, PMID 19234987, PMID 19433997, PMID 20354090, PMID 20686433, PMID 20843245, PMID 21396214, PMID 21458737, PMID 21684825, PMID 21723357, PMID 21829969, PMID 22078721, PMID 22285055, PMID 22384005, PMID 22403223, PMID 22422274, PMID 22483191, PMID 22888091, PMID 22952580, PMID 22997178, PMID 23017003, PMID 23433693, PMID 23582727, PMID 23941314, PMID 24011955, PMID 24086113, PMID 24279701, PMID 24636429, PMID 24648506, PMID 25286173, PMID 25579777, PMID 25688779, PMID 25785969, PMID 26196695
1OT2HL156812-01 (1), 2014 (1), 2019 (1), 2025 (1), R01HD038327 (1), R01MD016872 (1)